Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 20 12:25PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-1.38 Insider Own19.65% Shs Outstand58.89M Perf Week-11.43%
Market Cap200.81M Forward P/E- EPS next Y-1.31 Insider Trans0.00% Shs Float47.32M Perf Month-18.62%
Income-57.80M PEG- EPS next Q-0.33 Inst Own45.51% Short Float4.63% Perf Quarter-37.20%
Sales16.15M P/S12.43 EPS this Y41.89% Inst Trans-1.79% Short Ratio4.07 Perf Half Y95.98%
Book/sh3.13 P/B1.09 EPS next Y-22.22% ROA-28.68% Short Interest2.19M Perf Year17.59%
Cash/sh2.69 P/C1.27 EPS next 5Y34.60% ROE-34.37% 52W Range1.35 - 6.85 Perf YTD89.44%
Dividend Est.- P/FCF- EPS past 5Y-118.72% ROI-28.35% 52W High-50.22% Beta1.28
Dividend TTM- Quick Ratio12.19 Sales past 5Y0.00% Gross Margin76.90% 52W Low152.59% ATR (14)0.26
Dividend Ex-Date- Current Ratio12.19 EPS Y/Y TTM56.95% Oper. Margin-414.02% RSI (14)33.41 Volatility6.86% 6.50%
Employees50 Debt/Eq0.11 Sales Y/Y TTM- Profit Margin-358.00% Recom1.00 Target Price8.60
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q88.33% Payout- Rel Volume0.91 Prev Close3.42
Sales Surprise291.42% EPS Surprise74.85% Sales Q/Q- EarningsMay 14 BMO Avg Volume538.39K Price3.41
SMA20-9.63% SMA50-18.89% SMA2005.37% Trades Volume234,119 Change-0.29%
Date Action Analyst Rating Change Price Target Change
May-07-24Resumed Jefferies Buy $10
Feb-09-24Initiated BTIG Research Buy $8
Jan-23-24Initiated Leerink Partners Outperform $12
Sep-05-23Initiated RBC Capital Mkts Outperform $7
Nov-02-21Initiated Jefferies Buy $25
Nov-02-21Initiated Credit Suisse Outperform $19
Nov-02-21Initiated BofA Securities Neutral $16
Jun-10-24 07:30AM
May-30-24 07:30AM
May-14-24 03:53PM
07:30AM Loading…
May-09-24 07:30AM
Apr-12-24 09:55AM
Mar-28-24 04:30PM
Mar-27-24 07:30AM
Mar-26-24 12:00PM
Mar-21-24 01:53PM
Mar-13-24 08:00AM
Mar-07-24 04:30PM
04:45PM Loading…
Mar-05-24 04:45PM
Feb-27-24 08:00AM
Dec-29-23 04:30PM
Nov-28-23 07:00AM
Nov-07-23 04:30PM
Oct-23-23 11:27AM
Oct-13-23 09:00AM
Sep-27-23 09:18AM
Sep-14-23 05:03PM
Aug-31-23 04:01PM
Aug-23-23 08:35AM
Aug-11-23 07:00AM
Aug-01-23 04:01PM
Jun-30-23 05:00PM
May-30-23 08:30AM
06:45AM Loading…
May-24-23 06:45AM
May-11-23 07:00AM
Mar-31-23 05:00PM
Mar-30-23 02:16PM
Mar-22-23 06:45AM
Mar-16-23 07:30AM
Feb-13-23 08:00AM
Dec-23-22 04:45PM
Dec-01-22 06:45AM
Nov-01-22 06:30AM
Sep-30-22 05:00PM
Aug-15-22 07:00AM
Jul-12-22 06:45AM
Jun-28-22 06:35AM
Jun-21-22 10:40AM
May-19-22 06:35AM
May-13-22 08:03AM
May-07-22 10:34AM
Apr-27-22 06:35AM
Apr-13-22 06:35AM
Apr-08-22 01:05PM
Mar-29-22 11:00AM
Mar-22-22 06:35AM
Jan-10-22 11:17AM
Dec-15-21 08:00AM
Dec-09-21 08:30AM
Nov-15-21 07:15AM
Nov-10-21 08:00AM
Oct-08-21 03:31PM
Oct-07-21 10:24PM
Pyxis Oncology, Inc. engages in the business of developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. The firm focuses on the development of product candidates to directly kill tumor cells and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion. The company was founded by David Steinberg, Shaan C. Gandhi, and John L. Flavin on June 11, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Connealy Pamela AnnCFO and COOSep 28 '23Buy1.878,00014,960818,532Sep 28 04:32 PM
Connealy Pamela AnnCFO and COOSep 27 '23Buy1.856,42611,868810,532Sep 27 06:36 PM
Wadhane JitendraChief Accounting OfficerSep 27 '23Buy1.872,5004,675226,937Sep 27 06:37 PM
Connealy Pamela AnnCFO and COOSep 25 '23Buy1.6712,00020,044804,106Sep 25 05:04 PM
Wadhane JitendraChief Accounting OfficerSep 25 '23Buy1.775,0008,850224,437Sep 25 05:05 PM
Connealy Pamela AnnCFO and COOSep 22 '23Buy1.745,0008,695792,106Sep 22 07:34 PM
Wadhane JitendraChief Accounting OfficerSep 22 '23Buy1.742,5004,349219,437Sep 22 07:35 PM
Sullivan LaraPresident and CEOSep 18 '23Sale2.108,54117,9362,403,882Sep 18 07:03 PM
Sullivan LaraPresident and CEOSep 14 '23Sale2.251002252,412,423Sep 18 07:03 PM
Sullivan LaraPresident and CEOSep 13 '23Sale2.273,0006,8162,597,265Sep 13 08:16 PM
Sullivan LaraPresident and CEOSep 12 '23Sale2.254,91711,0712,600,265Sep 13 08:16 PM
Sullivan LaraPresident and CEOSep 11 '23Sale2.2720,00045,4142,605,182Sep 13 08:16 PM